Stockreport

Teva and Sanofi’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease

Teva Pharmaceutical Industries Limited American Depositary Shares  (TEVA) 
Last teva pharmaceutical industries limited american depositary shares earnings: 2/13 04:01 pm Check Earnings Report
US:NYSE Investor Relations: ir.tevapharm.com
PDF In the RELIEVE UCCD LTE phase 2b study, duvakitug showed robust, durable efficacy for an additional 44 weeks in UC and CD patients who had responded after 14 weeks of in [Read more]